OPEN END TURBO CALL WARRANT - MODERNA | Delayed Deutsche Boerse AG 05:14:11 2024-06-27 am EDT | ||
| 3.23 EUR | -8.24% |
|
| Current month | -31.65% | ||
| 1 month | -53.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 3.23 | -8.24% |
| 24-06-26 | 3.52 | -24.14% |
| 24-06-25 | 4.64 | +1.75% |
| 24-06-24 | 4.56 | +3.87% |
| 24-06-21 | 4.39 | +0.23% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 05:14 am EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| WKN | UM0446 |
| ISIN | DE000UM04465 |
| Date issued | 2023-12-18 |
| Strike | 87.63 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.62 € |
|---|---|
| Lowest since issue | 0.121 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.4
USD
Average target price
145.9
USD
Spread / Average Target
+19.11%
- Stock Market
- Certificates
- Certificat
